GW Pharma in Japan Cannabis Tie-Up (Japan)
This article was originally published in PharmAsia News
Japan-based Otsuka Pharmaceutical and Britain-based GW Pharmaceuticals have signed a deal to co-develop cannabis medicine for treating cancer and aliments in the central nervous system. Otsuka will invest $9 million into cannabis research over a three year period. Otsuka this year also signed a deal with GW for worldwide development and marketing rights to GW's drug Sativex. (Click here for more
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.